OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
SMCI
Super Micro Computer, Inc.
SMCI has the edge over OSCR overall, supported by stronger valuation and stronger modeled upside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SMCI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Strong |
SMCI's revenue, profitability and balance sheet are currently strong, but its cash flow is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SMCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.3x | $26.99 | — |
| Current | 5.7x | $26.99 | — |
| Cheap | 13x | $61.50 | +128% |
| Fair | 19x | $88.86 | +229% |
| Expensive | 26x | $125 | +363% |
Historical ranges are pointers, not guarantees.
SMCI has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SMCI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Moderate | |
| Low |
Analysts expect strong earnings and revenue growth for SMCI, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SMCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.22 | +31% |
| Q3 2026 | $4.75 | +274% |
| Q2 2026 | $3.26 | +94% |
| Q1 2026 | $1.91 | +4.4% |
| Q4 2025 | $1.36 | -41% |
| Q3 2025 | $1.27 | -45% |
| Q2 2025 | $1.68 | -13% |
| Q1 2025 | $1.83 | +2.8% |
| Q4 2024 | $2.32 | +81% |
SMCI has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SMCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.9B | +298% |
| Q2 2026 | $11.1B | +93% |
| Q1 2026 | $10.2B | +123% |
| Q4 2025 | $12.7B | +123% |
| Q3 2025 | $5B | -15% |
| Q2 2025 | $5.8B | +7.5% |
| Q1 2025 | $4.6B | +19% |
| Q4 2024 | $5.7B | +55% |
SMCI's revenue has grown year over year for four quarters in a row: $19.9B last quarter, up 298% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +6.7 points |
| Q2 2026 | 13% | +9.4 points |
| Q1 2026 | 6.1% | +2.9 points |
| Q4 2025 | 3.7% | -2.8 points |
| Q3 2025 | 3.6% | -5 points |
| Q2 2025 | 4% | -1.4 points |
| Q1 2025 | 3.2% | -6.6 points |
| Q4 2024 | 6.5% | -3.7 points |
SMCI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SMCI on cash generation, producing positive trailing cash flow while its opponent burns cash.
SMCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$475.6M | +$474.2M |
| Q2 2026 | $718.7M | -15% |
| Q1 2026 | -$6.7B | -1227% |
| Q4 2025 | -$45.1M | +$222.2M |
| Q3 2025 | -$949.8M | -360% |
| Q2 2025 | $840.9M | +$1.5B |
| Q1 2025 | $594.1M | +$2.2B |
| Q4 2024 | -$267.3M | +$342.5M |
SMCI's free cash flow was −$6.5B over the past year, against $218M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SMCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +52M shares |
| 1 year | +13% | +86.1M shares |
| 3 years | +31% | +178M shares |
| 5 years | +42% | +220M shares |
| Available history | +44% | +229M shares |
SMCI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $12M |
| Q1 2021 | $43.1M |
| Q4 2020 | $46.4M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SMCI on leverage, with a lower net debt burden relative to earnings.
SMCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 0.2x | Very low |
SMCI has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SMCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 19.1 | Oversold |
SMCI's weekly RSI is 41 (neutral) and its Stochastic is 19 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SMCI PE vs Technology Sector
| Metric | SMCI | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 28x | 80% below |
| PE % | 0 | 35 | 35 pts below |
SMCI has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SMCI on trend strength, trading above more of its moving averages.
SMCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.3 | 23% below |
| 20 week MA | $34.2 | 21% below |
| 50 week MA | $32.3 | 17% below |
| 100 week MA | $36.9 | 27% below |
| 200 week MA | $39.8 | 32% below |
SMCI is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SMCI on returns for 2026, with the stronger performance.
SMCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.41 | $3.05 | +27% |
| 2021 | $3.05 | $4.27 | +40% |
| 2022 | $4.27 | $8.22 | +93% |
| 2023 | $8.22 | $28.4 | +246% |
| 2024 | $28.4 | $32.0 | +12% |
| 2025 | $32.0 | $30.6 | -4.2% |
| 2026 YTD | $30.6 | $27.0 | -12% |
SMCI has finished higher in five of the last six years, two of them by more than 50%. It's down 12% so far in 2026.